# Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma

> **NCT00301418** · PHASE1,PHASE2 · COMPLETED · sponsor: **Northwell Health** · enrollment: 11 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Anaplastic Astrocytoma

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00301418
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2016-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301418, "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00301418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*